Anti-hCD40L-hIgG1
-
Cat.code:
h40l-mab1
- Documents
ABOUT
Anti-human CD40L antibody - Human IgG1 (high effector functions)
Anti-hCD40L-hIgG1 is a biosimilar research antibody to Frexalimab. Frexalimab (SAR441344) is a humanized, second-generation, Fc-engineered IgG1 monoclonal antibody (mAb) targeting the human CD40 ligand (CD40L). It blocks the binding between CD40L to its receptor CD40. The Fc engineering of Frexalimab abrogates the platelet activation due to FcγRIIa stimulation. Frexalimab shows promising results across multiple trials in treating various autoimmune diseases, such as relapsing multiple sclerosis, alleviating fatigue in primary Sjögren’s syndrome, and improving glycemic control in diabetic patients.
Anti-hCD40L-hIgG1 comprises the variable region of Frexalimab and a human IgG1 constant region mediating high effector functions.
This antibody can be used together with HEK-Blue™ CD40L cells for screening and neutralization assay to block CD40L signaling induced by recombinant human CD40L (see figure).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct has been verified.
- Absence of endotoxins determined by the EndotoxDetect assay
All products are for internal research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
Human CD40L
Human
Sodium phosphate buffer, glycine, saccharose, stabilizing agents
Negative (tested using EndotoxDetect™ assay)
Neutralization assay
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hCD40L-hIgG1
-
Cat code:h40l-mab1
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Frexalimab and CD40L background
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L). It is designed to specifically block the binding between CD40L and CD40 [1].
CD40 Ligand (CD40L), also known as CD154, TRAP, or gp39, is a type II transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) family. It is mainly expressed in CD4+-T cells and interacts with CD40 on antigen-presenting cells to regulate both humoral and cellular immune responses [2-3]. The CD40 cytoplasmic domain binds directly to several TNF receptor-associated factors (TRAFs), and this interaction is thought to initiate CD40 signaling. CD40-mediated signaling results in NF-κB, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) activation.
CD40L-CD40 interactions are thought to play an important role in the pathogenesis of many diseases [5, 6]. Thus, blocking this interaction using agents, such as Frexalimab, has shown promising results across multiple trials in treating various autoimmune diseases, such as relapsing multiple sclerosis, alleviating fatigue in primary Sjögren’s syndrome, and improving glycemic control in diabetic patients [1].
1. Fatima T, et al., 2024. Frexalimab (SAR441344) as a potential multiautoimmune disorder tackling mAB targeting the CD40-CD40L pathway undergoing clinical trials: a review. Ann Med Surg (Lond). ;86(12):7305-7313.
2. Karnell J.L. et al., 2019. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 141:92-103.
3. Laman J.D. et al., 2017. Functions of CD40 and Its Ligand, gp39 (CD40L). Crit Rev Immunol. 37(2-6):371-420.
4. Elgueta R. et al., 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229, 152–172.
5. Seijkens T. et al., 2013. CD40–CD40L: Linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications. Diabetes and Vascular Disease Research. 10: 115-122.
6. Daoussis D. et al., 2004. Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol. 11(4):635-41.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
